| Title |
Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease
|
|---|---|
| Published in |
Cochrane database of systematic reviews, October 2006
|
| DOI | 10.1002/14651858.cd006257 |
| Pubmed ID | |
| Authors |
Giovanni FM Strippoli, Carmen Bonifati, Maria E Craig, Sankar D Navaneethan, Jonathan C Craig |
| Abstract |
Angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor antagonists (AIIRA) are considered to be equally effective for patients with diabetic kidney disease (DKD), but renal and not mortality outcomes have usually been considered. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 197 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Japan | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 194 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 36 | 18% |
| Researcher | 24 | 12% |
| Other | 16 | 8% |
| Student > Bachelor | 16 | 8% |
| Student > Postgraduate | 15 | 8% |
| Other | 39 | 20% |
| Unknown | 51 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 99 | 50% |
| Nursing and Health Professions | 9 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 4% |
| Agricultural and Biological Sciences | 8 | 4% |
| Neuroscience | 3 | 2% |
| Other | 17 | 9% |
| Unknown | 53 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 February 2023.
All research outputs
#4,132,410
of 23,750,517 outputs
Outputs from Cochrane database of systematic reviews
#6,690
of 12,754 outputs
Outputs of similar age
#10,823
of 68,317 outputs
Outputs of similar age from Cochrane database of systematic reviews
#27
of 72 outputs
Altmetric has tracked 23,750,517 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,754 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 33.5. This one is in the 47th percentile – i.e., 47% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 68,317 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 72 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.